投稿信息
投稿信息
員@2x.png)
審稿費(fèi)用
2500.0元/篇
（網(wǎng)友貢獻(xiàn)，非官方數(shù)據(jù)）
版面費(fèi)用
2650.0元/篇
（網(wǎng)友貢獻(xiàn)，非官方數(shù)據(jù)）
中國人發(fā)表比例
2023年中國人文章占該期刊總數(shù)量暫無數(shù)據(jù) (2022年為16.59%)
自引率
5.6 %
年文章數(shù)
2133
期刊官網(wǎng)
點(diǎn)擊查看
(點(diǎn)擊次數(shù):6934)
投稿鏈接
點(diǎn)擊查看
(點(diǎn)擊次數(shù):5748次)
作者需知
點(diǎn)擊查看
(點(diǎn)擊次數(shù):4158次)
NCBI查詢
偏重的研究方向
期刊簡介
稿件收錄要求
稿件收錄要求
Journal for ImmunoTherapy of Cancer?(JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.?
Journal information
Publication Model
Open access
Frequency
Continuous
Launch date
2013
Indexed by
Web of Science Core Collection: Science Citation Index Expanded; MEDLINE (Index Medicus), PubMed Central, Scopus, DOAJ, Google Scholar
Peer Review Model
Single anonymised; the names of reviewers are hidden from the author
Print ISSN
N/A
Online ISSN
2051-1426
Journal Statistics 2023
Acceptance rate: 21%
?
Speed Time to first decision without review: 6 days (median) Time to first decision with review: 43 days (median) Time from acceptance to publication: 26 days (median)
Impact Impact Factor (JCR): 10.9 Impact Factor rank : 29/241 (Oncology), 18/161 (Immunology) 5 Year Impact Factor: 12.6 Journal Citation Indicator: 1.87 Eigenfactor: 0.04859 Citescore: 16.8 Citescore rank: 26/366 Scimago Journal rank (SJR): 3.403
Reach Total content views: 987,270 Total Altmetric mentions: 6,350
常用鏈接
期刊論壇
|
中國SCI論文
|
期刊介紹
|
投稿信息
|
雜志官網(wǎng)
|
投稿鏈接
|
作者需知
|
PMC鏈接
|
Pubmed全文檢索
